APOB
Apolipoprotein B-100
As of the edition of 20 October 2026, APOB (apolipoprotein B-100, UniProt P04114) has 1 drug tested at it and 2 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P04114
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 8
- Disease areas
- Nutrition and metabolism; Inherited and neonatal; Heart and blood vessels; Nervous system
- Registered trials of its drugs
- 19
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mipomersen | Marketed | Phase 3 | Ends 2027 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Undetermined | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Kastle Therapeutics | Route B |
The other 1 company at APOB
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at APOB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.